Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829750 | 1.00 | TSHR (0.60) | TSHRBRD4PKMALDH1A1KMT2A | |
| SCHEMBL829752 | 1.00 | TSHR (0.60) | TSHRBRD4PKMALDH1A1KMT2A | |
| SCHEMBL835910 | 1.00 | TSHR (0.60) | TSHRBRD4PKMALDH1A1KMT2A | |
| SCHEMBL28849555 | 0.76 | DAO (0.41) | BRD4ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL111475 | 0.76 | TSHR (1.00) | TSHRPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL14393160 | 0.76 | TSHR (1.00) | TSHRPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL8746347 | 0.76 | TSHR (1.00) | TSHRPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL14365934 | 0.76 | TSHR (1.00) | TSHRPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL3201023 | 0.76 | TSHR (1.00) | TSHRPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL8875725 | 0.76 | TSHR (1.00) | TSHRPKMALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| WO-2008046232-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | YUDIN ANDREI K (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | QDPR, VIP, AAAS | TSHR 3191/4885BRD4 3532/4885PKM 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.